| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
267.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.78 - $10.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
29,851 |
83,116 |
204,188 |
| Total Sell Value |
$0 |
$149,864 |
$489,708 |
$2,829,450 |
| Total People Sold |
0 |
12 |
13 |
15 |
| Total Sell Transactions |
0 |
12 |
15 |
48 |
| End Date |
2024-08-29 |
2024-05-28 |
2023-11-28 |
2022-11-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Abi-Saab Walid |
Chief Medical Officer |
• – – |
2024-06-26 |
4 |
S |
$4.36 |
$6,309 |
D/D |
(1,447) |
115,253 |
|
-26% |
|
| Balachandran Madhavan |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
31,839 |
|
- |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
22,488 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
31,836 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
14,581 |
|
- |
|
| Post Leonard E |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
24,079 |
|
- |
|
| Meek David D. |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
28,332 |
|
- |
|
| Gut Robert |
Director |
– • – |
2024-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,080 |
52,245 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2024-06-17 |
4 |
S |
$4.80 |
$7,733 |
D/D |
(1,611) |
164,837 |
|
-39% |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2024-06-17 |
4 |
S |
$4.81 |
$14,122 |
D/D |
(2,936) |
115,707 |
|
-39% |
|
| Post Leonard E |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.14 |
$11,421 |
D/D |
(2,222) |
15,999 |
|
-23% |
|
| Soteropoulos Paula |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.14 |
$11,411 |
D/D |
(2,220) |
20,203 |
|
-23% |
|
| Meek David D. |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.12 |
$11,412 |
D/D |
(2,229) |
20,252 |
|
-23% |
|
| Balachandran Madhavan |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.12 |
$11,423 |
D/D |
(2,231) |
23,759 |
|
-23% |
|
| Springhorn Jeremy P. |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.12 |
$11,423 |
D/D |
(2,231) |
23,756 |
|
-23% |
|
| Gut Robert |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.12 |
$17,940 |
D/D |
(3,504) |
44,165 |
|
-23% |
|
| Kaye Jack |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.16 |
$11,445 |
D/D |
(2,218) |
6,501 |
|
-23% |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2024-06-13 |
4 |
S |
$5.14 |
$11,416 |
D/D |
(2,221) |
14,408 |
|
-23% |
|
| Potts Jeannette |
Chief Legal Officer |
• – – |
2024-06-13 |
4 |
S |
$4.98 |
$23,809 |
D/D |
(4,781) |
91,819 |
|
-23% |
|
| Potts Jeannette |
Chief Legal Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
49,500 |
96,600 |
|
- |
|
| Abi-Saab Walid |
Chief Medical Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
49,500 |
116,700 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
49,500 |
166,448 |
|
- |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
590,839 |
|
- |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
118,643 |
|
- |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2024-02-26 |
4 |
S |
$6.47 |
$61,174 |
D/D |
(9,455) |
85,643 |
|
41% |
|
355 Records found
|
|
Page 1 of 15 |
|
|
0.03 (0.5%) 
